CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
2.4813
2.74%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0674
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

OncoCyte Corp ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.5513
Open* 2.4913
1-Year Change* 711.5%
Day's Range* 2.4813 - 2.5013
52 wk Range 2.08-9.90
Average Volume (10 days) 5,940.00
Average Volume (3 months) 393.26K
Market Cap 27.34M
P/E Ratio -100.00K
Shares Outstanding 8.26M
Revenue 1.46M
EPS -3.38
Dividend (Yield %) N/A
Beta 0.76
Next Earnings Date Apr 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 2.4813 -0.0100 -0.40% 2.4913 2.5013 2.4813
Apr 18, 2024 2.5513 -0.0200 -0.78% 2.5713 2.6313 2.4813
Apr 17, 2024 2.5913 -0.0600 -2.26% 2.6513 2.6613 2.5613
Apr 16, 2024 2.7213 0.1500 5.83% 2.5713 2.7213 2.4813
Apr 15, 2024 2.5213 0.0300 1.20% 2.4913 2.5713 2.4913
Apr 12, 2024 2.6613 -0.5700 -17.64% 3.2313 3.2713 2.4113
Apr 11, 2024 2.9413 0.1100 3.89% 2.8313 2.9713 2.8313
Apr 10, 2024 2.9113 0.0100 0.34% 2.9013 2.9513 2.9013
Apr 9, 2024 2.8713 0.0600 2.13% 2.8113 2.8713 2.8113
Apr 8, 2024 2.8413 0.0000 0.00% 2.8413 2.9213 2.8313
Apr 5, 2024 2.8813 0.0900 3.22% 2.7913 2.8813 2.7613
Apr 4, 2024 2.8813 0.0900 3.22% 2.7913 2.9213 2.7913
Apr 3, 2024 2.8913 0.0000 0.00% 2.8913 2.8913 2.8113
Apr 2, 2024 2.8113 -0.0500 -1.75% 2.8613 2.9013 2.7713
Apr 1, 2024 2.9013 0.1100 3.94% 2.7913 2.9113 2.7913
Mar 28, 2024 2.9213 -0.0100 -0.34% 2.9313 2.9313 2.8413
Mar 27, 2024 2.9313 0.0000 0.00% 2.9313 2.9513 2.9313
Mar 26, 2024 2.9713 0.0400 1.36% 2.9313 2.9813 2.9313
Mar 25, 2024 3.0013 0.0300 1.01% 2.9713 3.0013 2.9313
Mar 22, 2024 2.9913 -0.0500 -1.64% 3.0413 3.0413 2.9313

OncoCyte Corporation Events

Time (UTC) Country Event
Thursday, May 9, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 OncoCyte Corp Earnings Release
Q1 2024 OncoCyte Corp Earnings Release

Forecast

-

Previous

-
Friday, June 21, 2024

Time (UTC)

17:00

Country

US

Event

OncoCyte Corp Annual Shareholders Meeting
OncoCyte Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, August 7, 2024

Time (UTC)

20:00

Country

US

Event

Q2 2024 OncoCyte Corp Earnings Release
Q2 2024 OncoCyte Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.958 2.198 1.216 0 0
Total Operating Expense 18.955 54.782 30.927 22.392 15.202
Selling/General/Admin. Expenses, Total 21.533 20.392 23.282 15.445 8.688
Research & Development 6.965 4.807 9.378 6.794 6.514
Operating Income -17.997 -52.584 -29.711 -22.392 -15.202
Interest Income (Expense), Net Non-Operating -0.548 -0.25 -1.502 -0.031 -0.643
Net Income Before Taxes -18.612 -52.871 -31.186 -22.426 -15.754
Net Income After Taxes -18.612 -43.61 -29.932 -22.426 -15.754
Net Income Before Extra. Items -18.612 -43.61 -29.932 -22.426 -15.754
Net Income -72.902 -64.097 -29.932 -22.426 -15.754
Income Available to Common Excl. Extra. Items -19.132 -43.61 -29.932 -22.426 -15.754
Income Available to Common Incl. Extra. Items -73.422 -64.097 -29.932 -22.426 -15.754
Diluted Net Income -73.422 -64.097 -29.932 -22.426 -15.754
Diluted Weighted Average Shares 5.54 4.446 3.2739 2.5648 1.8925
Diluted EPS Excluding Extraordinary Items -3.45343 -9.80882 -9.14261 -8.74376 -8.32444
Diluted Normalized EPS 0.19007 -9.61715 -9.05883 -8.68411 -8.32444
Other, Net -0.067 -0.037 0.027 -0.003 0.091
Total Extraordinary Items -54.29 -20.487
Unusual Expense (Income) 20.185 1.311 0.422 0.153
Revenue 0.958 2.198 1.216
Cost of Revenue, Total 0.976 0.778 1.855
Gross Profit -0.018 1.42 -0.639
Other Operating Expenses, Total -31.019 27.266 -4.01
Depreciation / Amortization 0.315 0.228
Total Adjustments to Net Income -0.52 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.463 0.297 0.958 1.017 0.237
Revenue 0.463 0.297 0.958 1.017 0.237
Cost of Revenue, Total 0.191 0.287 0.976 2.191 0.206
Gross Profit 0.272 0.01 -0.018 -1.174 0.031
Total Operating Expense 8.757 -5.553 18.955 10.238 1.863
Selling/General/Admin. Expenses, Total 3.855 4.107 21.533 9.21 5.448
Research & Development 1.924 1.764 6.965 4.125 2.363
Other Operating Expenses, Total 1.795 -18.307 -31.019 -6.142 -6.359
Operating Income -8.294 5.85 -17.997 -9.221 -1.626
Interest Income (Expense), Net Non-Operating -0.023 0.111 -0.548 -0.174 -0.016
Other, Net -0.016 -0.002 -0.067 0.062 0.278
Net Income Before Taxes -8.333 5.959 -18.612 -9.333 -1.364
Net Income After Taxes -8.333 5.959 -18.612 -9.333 -1.364
Net Income Before Extra. Items -8.333 5.959 -18.612 -9.333 -1.364
Net Income -8.333 3.033 -72.902 -9.333 -8.3
Income Available to Common Excl. Extra. Items -8.644 5.729 -19.132 -9.555 -1.436
Income Available to Common Incl. Extra. Items -8.644 2.803 -73.422 -9.555 -8.372
Diluted Net Income -8.644 2.803 -73.422 -9.555 -8.372
Diluted Weighted Average Shares 8.09 7.56 5.54 5.9305 5.652
Diluted EPS Excluding Extraordinary Items -1.06848 0.7578 -3.45343 -1.61116 -0.25407
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.98937 1.58228 0.19007 -1.51707 -0.23213
Unusual Expense (Income) 0.64 6.233 20.185 0.558 0.124
Depreciation / Amortization 0.352 0.363 0.315 0.296 0.081
Total Extraordinary Items 0 -2.926 -54.29 -6.936
Total Adjustments to Net Income -0.311 -0.23 -0.52 -0.222 -0.072
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 25.536 39.143 9.226 22.956 8.642
Cash and Short Term Investments 20.426 36.509 7.818 22.451 8.462
Cash & Equivalents 19.993 35.605 7.143 22.072 8.034
Short Term Investments 0.433 0.904 0.675 0.379 0.428
Prepaid Expenses 0.977 0.693 1.205 0.505 0.18
Other Current Assets, Total 2.121
Total Assets 100.091 159.563 55.419 39.859 9.518
Property/Plant/Equipment, Total - Net 10.851 8.527 6.524 3.728 0.614
Property/Plant/Equipment, Total - Gross 15.047 11.242 7.964 4.071 1.562
Accumulated Depreciation, Total -4.196 -2.715 -1.44 -0.343 -0.948
Intangibles, Net 61.633 91.245 15.009 0
Other Long Term Assets, Total 2.071 1.964 2.056 2.211 0.262
Total Current Liabilities 12.106 14.12 8.996 4.44 5.561
Accounts Payable 1.253 2.447 0.432 0.469 0.166
Accrued Expenses 8.731 10.256 5.423 2.769 2.109
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.117 1.417 2.541 1.196 1.185
Other Current Liabilities, Total 2.005 0.6 0.006 2.101
Total Liabilities 60.497 94.346 21.936 9.021 6.095
Total Long Term Debt 0 0.117 1.729 1.963 0.534
Capital Lease Obligations 0 0.117 0.221 0.058 0.187
Total Equity 39.594 65.217 33.483 30.838 3.423
Preferred Stock - Non Redeemable, Net 5.302 0 0
Common Stock 294.929 252.954 157.16 124.583 74.742
Retained Earnings (Accumulated Deficit) -260.676 -187.774 -123.677 -93.745 -71.319
Other Equity, Total 0.039 0.037 0
Total Liabilities & Shareholders’ Equity 100.091 159.563 55.419 39.859 9.518
Total Common Shares Outstanding 5.9322 4.6116 3.45585 2.8516 2.0332
Long Term Debt 0 1.508 1.905 0.347
Long Term Investments 0 13.417 10.964
Other Liabilities, Total 48.391 80.109 11.211 2.618
Total Receivables, Net 2.012 1.637 0.203
Accounts Receivable - Trade, Net 2.012 1.437 0.203
Goodwill, Net 0 18.684 9.187
Total Inventory 0.304
Total Preferred Shares Outstanding 0.00001
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 16.917 20.984 15.648 25.536 36.636
Cash and Short Term Investments 14.224 17.898 12.356 20.426 32.472
Cash & Equivalents 13.783 17.368 11.803 19.993 32.053
Short Term Investments 0.441 0.53 0.553 0.433 0.419
Total Receivables, Net 1.882 1.716 1.901 2.012 1.99
Accounts Receivable - Trade, Net 1.882 1.716 1.901 2.012 1.99
Prepaid Expenses 0.672 1.179 0.97 0.977 2.174
Total Assets 81.587 87.54 82.8 100.091 157.344
Property/Plant/Equipment, Total - Net 5.833 7.888 8.424 10.851 11.593
Property/Plant/Equipment, Total - Gross 11.652 13.198 13.196 15.047 15.73
Accumulated Depreciation, Total -5.819 -5.31 -4.772 -4.196 -4.137
Goodwill, Net 0 18.684
Intangibles, Net 56.617 56.639 56.661 61.633 88.365
Long Term Investments
Other Long Term Assets, Total 2.22 2.029 2.067 2.071 2.066
Total Current Liabilities 8.033 7.667 9.43 12.106 12.952
Accounts Payable 1.136 0.875 1.395 1.253 1.826
Accrued Expenses 6.777 6.597 7.71 8.731 11.013
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.03 0.06 0.089 0.117 0.113
Other Current Liabilities, Total 0.09 0.135 0.236 2.005
Total Liabilities 39.102 39.215 39.335 60.497 75.411
Total Long Term Debt 0 0 0 0 0.031
Long Term Debt
Capital Lease Obligations 0 0 0 0 0.031
Other Liabilities, Total 31.069 31.548 29.905 48.391 62.428
Total Equity 42.485 48.325 43.465 39.594 81.933
Common Stock 309.995 309.535 295.533 294.929 292.536
Retained Earnings (Accumulated Deficit) -272.465 -265.976 -257.643 -260.676 -215.698
Total Liabilities & Shareholders’ Equity 81.587 87.54 82.8 100.091 157.344
Total Common Shares Outstanding 8.261 8.241 5.96395 5.9322 5.93095
Other Equity, Total 0.032 0.041 0.043 0.039 0.019
Preferred Stock - Non Redeemable, Net 4.923 4.725 5.532 5.302 5.076
Other Current Assets, Total 0.139 0.191 0.421 2.121
Total Preferred Shares Outstanding 0.00001 0.00001 0.00001 0.00001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -72.902 -64.097 -29.932 -22.426 -15.754
Cash From Operating Activities -45.568 -35.941 -25.98 -19.715 -11.649
Cash From Operating Activities 1.528 0.844 0.313 0.344 0.438
Amortization 3.692 3.361 0.081 0 0.121
Non-Cash Items 24.056 35.415 4.413 3.922 2.553
Changes in Working Capital -1.942 -2.203 0.399 -1.555 0.993
Cash From Investing Activities -4.34 -13.961 -11.748 -12.415 -0.031
Capital Expenditures -4.34 -2.247 -1.227 -0.918 -0.031
Other Investing Cash Flow Items, Total 0 -11.714 -10.521 -11.497 0
Cash From Financing Activities 35.806 78.364 22.799 47.868 12.114
Financing Cash Flow Items -0.483 -3.065 -0.132 -3.288 -0.355
Issuance (Retirement) of Stock, Net 37.718 82.963 22.236 49.793 13.65
Issuance (Retirement) of Debt, Net -1.429 -1.534 0.695 1.363 -1.181
Net Change in Cash -14.102 28.462 -14.929 15.738 0.434
Cash Interest Paid 0.024 0.114 0.209 0.171 0.142
Deferred Taxes 0 -9.261 -1.254
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 3.033 -72.902 -27.924 -18.591 -10.291
Cash From Operating Activities -9.672 -45.568 -35.92 -24.568 -13.277
Cash From Operating Activities 0.45 1.528 1.062 0.671 0.287
Amortization 0.022 3.692 2.88 1.904 0.928
Deferred Taxes 0 0 0
Non-Cash Items -11.212 24.056 -9.589 -6.742 -2.309
Cash Interest Paid 0 0.024 0.024 0.021 0.013
Changes in Working Capital -1.965 -1.942 -2.349 -1.81 -1.892
Cash From Investing Activities 0 -4.34 -3.538 -2.679 -1.561
Capital Expenditures 0 -4.34 -3.538 -2.679 -1.561
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities -0.028 35.806 35.906 36.478 -0.355
Financing Cash Flow Items 0 -0.483 -0.483 -0.483 -0.001
Issuance (Retirement) of Stock, Net 0 37.718 37.718 37.718 0.031
Issuance (Retirement) of Debt, Net -0.028 -1.429 -1.329 -0.757 -0.385
Net Change in Cash -9.7 -14.102 -3.552 9.231 -15.193

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

OncoCyte Corporation Company profile

About OncoCyte Corp

Oncocyte Corporation is a molecular diagnostics company. The Company is engaged in developing and commercializing laboratory-developed tests (LDTs) to serve unmet medical needs across the cancer care continuum. The LTDs provide actionable information to physicians and patients to optimize treatment decisions, including the selection of immunotherapy. The Company focuses on the development of a non-invasive confirmatory blood test for lung cancer called DetermaDx. The DetermaDx is the test to predict a post-surgery patient’s risk of cancer recurrence and their response to chemotherapy in early-stage lung cancer. Its development pipeline includes TheraSure CNI Monitor, which is a blood-based test for immunotherapy monitoring, and TheraSure Transplant Monitor, a solid organ transplantation monitoring test. Its other DetermaIO, DetermaCNI, DetermaMx, Keytruda, Opdivo, Tecentriq and Imfinzi.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, OncoCyte Corp revenues increased from $1.2M to $7.7M. Net loss increased from $29.9M to $64.1M. Revenues reflect DetermaRx segment increase from $547K to $2.5M, Pharma Services segment increase from $669K to $1.5M, United States segment increase from $742K to $3.5M. Higher net loss reflects Fair Value Adjustments on Other Assets increase from $4M (income) to $27.3M (expense).

Industry: Bio Therapeutic Drugs

15 Cushing
IRVINE
CALIFORNIA 92618
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

BTC/USD

65,052.50 Price
+0.530% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

ETH/USD

3,176.15 Price
+0.770% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading